# A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

> **NCT04566601** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 390 (actual)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** BI 1358894
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04566601
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2022-12-09
- **Final completion:** 2023-01-25
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566601, "A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04566601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*